Is the worst over? Catalent touts GLP-1 and gene therapy business as it sticks to financial guidance
Catalent’s financial health appears to be on the mend thanks to specific segments of its manufacturing business, but the CDMO still has a long road to recovery.
In a surprise to analysts and observers, Catalent reaffirmed its full fiscal 2024 guidance, forecasting revenue of $4.3 billion to $4.5 billion. Part of the growth forecast for 2024 is attributed to a string of new anticipated regulatory approvals for therapies which it is contracted to manufacture.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.